Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/007—Preparations for dry skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/66—Microorganisms or materials therefrom
  • A61K35/74—Bacteria
  • A61K35/741—Probiotics
  • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
  • A61K35/745—Bifidobacteria
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
  • A61K8/9728—Fungi, e.g. yeasts
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/16—Emollients or protectives, e.g. against radiation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present disclosure mainly concerns at providing a novel active principle for preventing and/or treating dryness of keratinous substances and in particular skin described as dry.
• cutaneous dryness state is a physiological state which may be present in young subjects without any pathological cause, at least apparent pathological cause.
• the origin of this dryness may be constitutional or acquired.
• many external factors can result in drying of the skin or can aggravate the state of the skin which is already dry. Mention may be made, among these factors, of difficult climatic conditions, solar radiation, or exposure to certain chemical or therapeutic agents.
• Dry skin is often associated physiologically with a fall in the level of cutaneous hydration and with a detrimental change in the barrier function, measured by the imperceptible water loss. It is in particular characterized sensorially by a feeling of skin tightness and/or tension. For obvious reasons, these manifestations are sources of discomfort, indeed even of pain.
• probiotic microorganisms can prove to be particularly effective in the prevention and/or treatment of dry skin, with the proviso that they are employed in the form of a lysate.
• a subject-matter of the disclosure is the cosmetic use of an effective amount of a lysate of at least one microorganism of the genus Bifidobacterium species and/or one of its fractions for treating and/or preventing dryness and/or associated disorders of a keratinous substance, in particular dry epidermides, such as the skin or scalp.
• the present disclosure concerns the use of an effective amount of a lysate of at least one microorganism of the genus Bifidobacterium species and/or one of its fractions in the preparation of a composition intended to treat and/or prevent dryness and/or associated disorders of a keratinous substance.
• such a composition proves to be effective in treating ichthyoses, psoriasis, hyperkeratoses, topical dermatitides and dry dandruff states of the scalp.
• the present disclosure relates, according to another of its aspects, to the cosmetic use of an effective amount of a lysate of at least one microorganism of the genus Bifidobacterium species and/or one of its fractions in treating and/or preventing a dry dandruff state of the scalp, and more particularly dry dandruffs.
• the present disclosure concerns the use of an effective amount of a lysate of at least one microorganism of the genus Bifidobacterium species and/or one of its fractions in the preparation of a composition intended to treat and/or prevent a dry dandruff state of the scalp.
• the term “to prevent” means to reduce the risk of appearance of the phenomenon concerned.
• a subject-matter of the disclosure is a method, in particular a cosmetic method, for treating and/or preventing dryness and/or associated disorders of a keratinous substance, in particular dry epidermides, such as the skin or scalp, in a subject, comprising at least one step of administration to the said subject of at least an effective amount of a lysate of at least one microorganism of the genus Bifidobacterium species and/or one of its fractions.
• a subject-matter of the present disclosure is a cosmetic and/or dermatological composition, of use in particular for preventing and/or treating dry keratinous substances, in particular dry epidermides, such as the skin or scalp, comprising, in a physiologically acceptable carrier, at least an effective amount of a lysate of at least one microorganism of the genus Bifidobacterium species and/or one of its fractions, in combination with an effective amount of at least one additional microorganism, in particular a probiotic microorganism, distinct from said lysate.
• the expression “distinct from said lysate” means that it is possible to distinguish, within the composition, either two different microorganisms or two different forms of the same microorganism.
• this additional microorganism is then present in a form other than a lysate.
• the present disclosure concerns a cosmetic and/or dermatological composition, of use in particular for preventing and/or treating dry keratinous substances, in particular dry epidermides, such as the skin or scalp, comprising, in a physiologically acceptable carrier, at least an effective amount of a lysate of at least one microorganism of the genus Bifidobacterium species and/or one of its fractions, in combination with an effective amount of at least one moisturizing active principle in particular as described below.
• Urea and its derivatives are very particularly suitable as such.
• the lysate according to the disclosure can be administered by the oral route.
• the lysate according to the disclosure can be administered by the topical route.
• compositions comprising it are formulated in order to be compatible with the method of administration selected.
• dry skin is essentially expressed by a feeling of tightness and/or tension.
• the skin is also rough to the touch and appears covered with squamae.
• these squamae are profuse but not very visible to the naked eye. They becomes less numerous but increasingly visible to the naked eye when this disorder worsens.
• the dry dandruff states are chronic, frequent, recurring and socially disabling states. Stress and the winter period reinforce these states in the majority of the individuals.
• the integrity and homeostasis of the scalp are regulated by an assembly of parameters including sebum secretion and the intra-individual sensitivity.
• the skin of the scalp is irritated, and pruriginous, fragile, less hydrated and develops significant desquamation which is reflected a dry dandruff state.
• a dry dandruff state is different from a greasy dandruff state.
• the former is reflected in particular by the presence of white or grey squamae, dry and of small size, whereas the latter is characterized by greasy, large and yellow squamae.
• the origin of this cutaneous dryness can be of constitutional or acquired type.
• Pathologic constitutional dry skin is represented essentially by atopic dermatitis and ichthyoses. It is virtually independent of the external conditions.
• Atopic dermatitis is described as associated with a deficiency in the metabolism of the lipids of the stratum corneum and in particular of the ceramides.
• This pathology presents itself in the form of a more or less chronic xerosis affecting a large expanse of the body, associated or not associated with inflammatory and pruriginous eruptions by patches.
• Atopic dermatitides are also described as chronic inflammatory pathologies of the skin, often coexisting with other atopic pathologies, such as rhinitis, conjunctivitides and allergic asthma.
• atopic dermatitis is reflected by dry skin associated with dysfunctionings of the epidermal barrier. An increase in imperceptible water loss is nearly always encountered.
• the barrier function of the skin is detrimentally affected not only on the parts affected by eczema but also with regard to noninflammatory dry skin. This detrimental change accordingly facilitates the penetration of various substances from the environment into the skin.
• Ichthyoses are pathologies characterized by a genetic deficiency which affects the keratinization process at various stages. They are manifested by significant desquamation by patches.
• the pathologic constitutional dry skin concerned according to the disclosure is more particularly dry skin or dry scalp of noninflammatory origin.
• the involvement of external parameters such as exposure to chemical agents, to difficult climatic conditions, to solar radiation or alternatively certain therapeutic treatments (retinoids, for example), is determining. Under these external influences, the epidermis can then become temporarily and locally dry. This can concern any type of epidermis.
• cutaneous dryness can also be induced by an exogenous stress of chemical origin, for example of peeling type, or also of mechanical origin (rubbing, shaving).
• chemical origin for example of peeling type, or also of mechanical origin (rubbing, shaving).
• a peeling operation consists essentially in applying a chemical substance to the skin with the aim of bringing about limited and controlled destruction of the epidermis and of the surface layers of the dermis in order to improve certain disorders of the appearance of the skin.
• the first ablative laser beams produced with pulsed or scanned CO 2 lasers, have the immediate effect of vaporizing (or ablating) the epidermis and often the upper part of the dermis.
• a strip of the underlying dermis is generally also the site of thermal injury with denaturation and contraction of the collagen.
• reepithelization occurs starting from the hair follicles and other adnexa in addition to an upper dermal strip (“remodelling of the collagen”).
• the latest generation of lasers uses a system of conversion of the laser beam into a multitude of beams spaced out from one another in order to produce, on the skin, impacts spaced out from one another, thus maintaining, between the affected areas, areas of healthy skin not detrimentally changed.
• peeling thus has an action which, although controlled, remains irritating with regard to the surface of the epidermis and liable to induce cutaneous dryness.
• compositions, methods and uses according to the disclosure thus prove to be very particularly effective:
• the active principle under consideration according to the disclosure proves to be particularly advantageous in preventing and/or treating the expression of signs of weakness, such as, for example, the dryness which is generally reflected by a brittle aspect of the fibre. It thus makes it possible to confer a glossy appearance on the keratinous fibres, in particular on human hair and on the coats of animals.
• a lysate of microorganisms in accordance with the disclosure is not employed as agent for inhibiting adhesion of the pathogenic flora of the skin.
• microorganisms of the genus Bifidobacterium species used as active principles according to the disclosure are employed in the form of a lysate.
• a lysate commonly denotes a material obtained on conclusion of the destruction or dissolution of biological cells by a “cell lysis” phenomenon, thus resulting in the release of the intracellular biological constituents naturally present in the cells of the microorganism under consideration.
• lysate is used without distinction to denote the whole of the lysate obtained by lysis of the microorganism concerned or only a fraction of the latter.
• the lysate employed is thus formed all or in part of the intracellular biological constituents and of the wall and cell membrane constituents.
• the cell cytoplasmic fraction including enzymes, such as lactic acid dehydrogenase, phosphatases, phosphoketolases and transaldolases.
• enzymes such as lactic acid dehydrogenase, phosphatases, phosphoketolases and transaldolases.
• the constituents of the cell walls are in particular peptidoglycan, murein or mucopeptide and teichoic acid and the constituents of the cell membranes are compounds of glycerophospholipid.
• This cell lysis can be accomplished by various technologies, such as, for example, osmotic shock, heat shock, with ultrasound, or also under mechanical stress of centrifuging type, for example.
• this lysate can be obtained according to technology described in U.S. Pat. No. 4,464,362 and in particular according to the following protocol.
• the microorganism of Bifidobacterium species type under consideration is cultured anaerobically in an appropriate culture medium, for example according to the conditions described in the documents U.S. Pat. No. 4,464,362 and EP 43 128.
• the culture medium can be inactivated by pasteurization, for example at a temperature of 60 to 65° C. for 30 min.
• the microorganisms are then collected by a conventional separation technique, for example membrane filtration or centrifuging, and resuspended in a sterile physiological NaCl solution.
• the lysate can be obtained by disintegrating such a medium using ultrasound in order to release therefrom the cytoplasmic fractions, the cell wall fragments and the products resulting from the metabolism. Then all the components in their natural distribution are subsequently stabilized in a weakly acidic aqueous solution.
• a concentration of the order of 0.1 to 50% by weight, in particular of 1 to 20% by weight and especially of approximately 5% by weight of active material(s), with respect to the total weight of the lysate, is thus generally obtained.
• the lysate can be employed in different forms, in the form of a solution or in a pulverulent form.
• the microorganism belonging to the genus Bifidobacterium species is more particularly chosen from the species: Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis or Bifidobacterium pseudocatenulatum and their mixtures.
• the species Bifidobacterium longum is very particularly suitable for the disclosure.
• fraction more particularly denotes a fragment of the said microorganism which is effective in the treatment of dry epidermides by analogy with the said whole microorganism.
• the active principle forming the lysate belonging to the genus Bifidobacterium species can be formulated in a proportion of at least 0.0001% by weight (expressed as dry weight), in particular in a proportion of 0.001 to 20% by weight and more particularly in a proportion of 0.001 to 2% by weight, with respect to the total weight of the carrier or of the composition comprising it.
• the concentration of microorganism(s), in particular probiotic microorganism(s), can be adjusted so as to correspond to doses (expressed as microorganism equivalent) varying from 5 ⁇ 10 2 to 10 13 ufc/d and in particular from 10 5 to 10 11 ufc/d.
• this lysate is employed in combination with another microorganism.
• compositions according to the disclosure can in addition advantageously comprise at least one additional microorganism, in particular of probiotic type, and/or one of its fractions and/or one of its metabolites.
• probiotic microorganism is understood to mean a living microorganism which, when it is consumed in an appropriate amount, has a positive effect on the health of its host, “Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotic in Food Including Powder Milk with Live Lactic Acid Bacteria, 6 Oct. 2001”, and which can in particular improve the intestinal microbial balance.
• microorganisms which are suitable for the disclosure can be chosen in particular from the Ascomycetes, such as Saccharomyces, Yarrowia, Kluyveromyces, Torulaspora, Schizosaccharomyces pombe, Debaromyces, Candida, Pichia, Aspergillus and Penicillium , bacteria of the genus Bacteroides, Fusobacterium, Melissococcus, Propionibacterium, Enterococcus, Lactococcus, Staphylococcus, Peptostreptococcus, Bacillus, Pediococcus, Micrococcus, Leuconostoc, Weissella, Aerococcus, Oenococcus and Lactobacillus , and their mixtures.
• Ascomycetes such as Saccharomyces, Yarrowia, Kluyveromyces, Torulaspora, Schizosaccharomyces pombe, Debaromyces, Candida, Pi
• Ascomycetes which are particularly suitable for the present disclosure, of Yarrowia lipolitica and Kluyveromyces lactis , as well as Saccharomyces cerevisiae, Torulaspora, Schizosaccharamyces pombe, Candida and Pichia.
• probiotic microorganisms are Lactobacillus acidophilus, Lactobacillus alimentarius, Lactobacillus curvatus, Lactobacillus delbruckii subsp. Lactis, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus rhamnosus ( Lactobacillus GG), Lactobacillus sake, Lactococcus lactis, Streptococcus thermophilus, Staphylococccus carnosus , and Staphylococcus xylosus and their mixtures.
• probiotic microorganisms resulting from the group of the lactic bacteria such as, in particular, the Lactobacillus species. Mention may more particularly be made, by way of illustration of these lactic bacteria, of Lactobacillus johnsonii, Lactobacillus paracasei, Lactobacillus reuteri, Lactobacillus rhamnosus and their mixtures.
• the additional microorganism may or may not be the same species as that forming the lysate. However, when it is the same species, it is then present in a form other than a lysate, for example in a living form.
• Lactobacillus johnsonii in particular the strain deposited according to the Treaty of Budapest with the Institut Pasteur (28 rue du Dondel Roux, F-75024 Paris cedex 15) under the following designation CNCM I-1225.
• compositions for topical application according to the disclosure generally comprise from 0.0001 to 30%, in particular from 0.001 to 15% and more particularly from 0.1 to 10% of one or more additional microorganisms, in particular probiotic microorganisms.
• compositions according to the disclosure can be included in the compositions according to the disclosure in a living, semi-active or inactivated, or dead form.
• microorganism(s) or fraction(s) can also be introduced in the form of a powder, of a liquid, of a culture supernatant or one of its fractions, diluted or undiluted, or also concentrated or nonconcentrated.
• the amount of living microorganisms can vary from 10 3 to 10 15 ufc/g, in particular from 10 5 to 10 15 ufc/g and more particularly from 10 7 to 10 12 ufc/g of microorganisms per gram of composition.
• compositions according to the disclosure can be provided in all the formulation forms normally available for the method of administration selected.
• the carrier can be of various natures, depending on the type of composition under consideration.
• compositions intended for administration by the external topical route that is to say at the surface of a keratinous substance, such as the skin
• they can be aqueous, aqueous/alcoholic or oily solutions, dispersions of the type of solutions or dispersions of the lotion or serum type, emulsions of a liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O/W) or vice versa (W/O), or of suspensions or emulsions of the cream type, aqueous or anhydrous gels, microemulsions, microcapsules, microparticles or vesicular dispersions of ionic and/or nonionic type.
• compositions are prepared according to the usual methods.
• compositions can in particular constitute cleansing, protecting, treating or care creams for the face, for the hands, for the feet, for the major anatomical folds or for the body (for example, day creams, night creams, make-up-removing creams, cream foundations or sun creams), make-up products, such as liquid foundations, make-up-removing milks, protective or care body milks, aftersun milks, lotions, gels or foams for caring for the skin, such as cleansing or disinfecting lotions, sun lotions, artificial tanning lotions, bath compositions, deodorant compositions comprising a bactericidal agent, aftershave gels or lotions, depilatory creams or compositions for combating insect stings and bites.
• make-up products such as liquid foundations, make-up-removing milks, protective or care body milks, aftersun milks, lotions, gels or foams for caring for the skin
• compositions according to the disclosure can also consist of solid preparations constituting cleansing soaps or bars.
• They can also be used for the scalp in the form of solutions, creams, gels, emulsions or foams or also in the form of aerosol compositions also comprising a pressurized propellant.
• the proportion of the fatty phase can range from 5 to 80% by weight and preferably from 5 to 50% by weight, with respect to the total weight of the composition.
• the oils, the emulsifiers and the coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the cosmetic and/or dermatological field.
• the emulsifier and the coemulsifier can be present in the composition in a proportion ranging from 0.3 to 30% by weight and preferably from 0.5 to 20% by weight, with respect to the total weight of the composition.
• the fatty phase can represent more than 90% of the total weight of the composition.
• the formulation forms intended for topical administration can also comprise adjuvants which are normal in the cosmetic, pharmaceutical and/or dermatological field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active principles, preservatives, antioxidants, solvents, fragrances, fillers, screening agents, bactericides, odour absorbers and colouring materials.
• adjuvants which are normal in the cosmetic, pharmaceutical and/or dermatological field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active principles, preservatives, antioxidants, solvents, fragrances, fillers, screening agents, bactericides, odour absorbers and colouring materials.
• the amounts of these various adjuvants are those conventionally used in the field under consideration, for example from 0.01 to 20% of the total weight of the composition.
• These adjuvants depending on their nature, can be introduced into the fatty phase and/or into the aqueous phase.
• fatty substances which can be used in the disclosure, of mineral oils, such as, for example, hydrogenated polyisobutene and liquid petrolatum, vegetable oils, such as, for example, a liquid fraction of shea butter, sunflower oil and apricot kernel oil, animal oils, such as, for example, perhydrosqualene, synthetic oils, in particular Purcellin oil, isopropyl myristate and ethylhexyl palmitate, unsaturated fatty acids and fluorinated oils, such as, for example, perfluoropolyethers.
• mineral oils such as, for example, hydrogenated polyisobutene and liquid petrolatum
• vegetable oils such as, for example, a liquid fraction of shea butter, sunflower oil and apricot kernel oil
• animal oils such as, for example, perhydrosqualene
• synthetic oils in particular Purcellin oil, isopropyl myristate and ethylhexyl palmitate
• unsaturated fatty acids such as, for example,
• Use may also be made of fatty alcohols, fatty acids, such as, for example, stearic acid, and such as, for example, waxes, in particular paraffin wax, carnauba wax and beeswax.
• fatty acids such as, for example, stearic acid
• waxes such as, for example, waxes, in particular paraffin wax, carnauba wax and beeswax.
• silicone compounds such as silicone oils, for example cyclomethicones and dimethicones, silicone waxes, silicone resins and silicone gums.
• emulsifiers which can be used in the disclosure, for example, of glyceryl stearate, polysorbate 60, the cetearyl alcohol/oxyethylenated cetearyl alcohol comprising 33 mol of ethylene oxide mixture sold under the name Sinnowax AOTM by Henkel, the PEG-6/PEG-32/Glycol Stearate mixture sold under the name Tefose® 63 by Gattefossé, PPG-3 myristyl ether, silicone emulsifiers, such as cetyl dimethicone copolyol, and sorbitan mono- or tristearate, PEG-40 stearate or oxyethylenated (20 EO) sorbitan monostearate.
• glyceryl stearate polysorbate 60
• cetearyl alcohol/oxyethylenated cetearyl alcohol comprising 33 mol of ethylene oxide mixture sold under the name Sinnowax AOTM by Henkel
• solvents which can be used in the disclosure of lower alcohols, in particular ethanol and isopropanol, or propylene glycol.
• composition of the disclosure can also advantageously comprise a thermal and/or mineral water chosen in particular from water from Vittel, water from the Vichy basin and water from La Roche Posay.
• hydrophilic gelling agents of carboxyl polymers, such as carbomer, acrylic copolymers, such as acrylate/alkylacrylate copolymers, polyacrylamides, in particular the mixture of polyacrylamide, C13-14 Isoparaffin and Laureth-7 sold under the name Sepigel 305TM by SEPPIC, polysaccharides, such as cellulose derivatives, for example hydroxyalkylcelluloses, in particular hydroxypropylcellulose and hydroxyethylcellulose, natural gums, such as guar, locust bean and xanthan gums, and clays.
• carboxyl polymers such as carbomer, acrylic copolymers, such as acrylate/alkylacrylate copolymers
• polyacrylamides in particular the mixture of polyacrylamide, C13-14 Isoparaffin and Laureth-7 sold under the name Sepigel 305TM by SEPPIC
• polysaccharides such as cellulose derivatives, for example hydroxyalkylcelluloses, in particular hydroxyprop
• lipophilic gelling agents of modified clays, such as bentones, metal salts of fatty acids, such as aluminium stearates, and hydrophobic silica, or also ethylcellulose and polyethylene.
• compositions and in particular of food supplements are possible for ingestion. They are formulated by standard processes for producing tablets, including sugar-coated tablets, capsules, including hard gelatin capsules, gels or emulsions.
• the active principle(s) according to the disclosure can be incorporated in any other form of food supplement or enriched food, for example food bars, or compacted or uncompacted powders.
• the powders can be diluted with water or in fizzy drinks, dairy products or soya derivatives or can be incorporated in food bars.
• the additional microorganisms under consideration according to the disclosure can be formulated in compositions in an encapsulated form, so as to significantly improve their lifetime.
• the presence of a capsule can in particular slow down or prevent the decomposition of the microorganism in the gastrointestinal tract.
• topical or oral compositions or the combinations according to the disclosure can additionally comprise several other active principles.
• vitamins B3, B5, B6, B8, C, E or PP Mention may be made, as active principles conventionally employed, of vitamins B3, B5, B6, B8, C, E or PP, niacin, carotenoids, polyphenols and minerals, such as zinc, calcium, magnesium, and the like.
• an antioxidant complex comprising vitamins C and E and at least one carotenoid, in particular a carotenoid chosen from ⁇ -carotene, lycopene, astaxanthin, zeaxanthin and lutein, flavonoids, such as catechins, hesperidin, proanthocyanidins and anthocyanins.
• a carotenoid chosen from ⁇ -carotene, lycopene, astaxanthin, zeaxanthin and lutein, flavonoids, such as catechins, hesperidin, proanthocyanidins and anthocyanins.
• At least one prebiotic or one mixture of prebiotics may also be involved. More particularly, these prebiotics can be chosen from oligosaccharides, produced from glucose, galactose, xylose, maltose, sucrose, lactose, starch, xylan, hemicellulose, inulin, gums of acacia type, for example, or one of their mixtures. More particularly, the oligosaccharide comprises at least one fructooligosaccharide. More particularly, this prebiotic can comprise a mixture of fructooligosaccharide and of inulin.
• hydrophilic active principles of proteins or protein hydrolysates, amino acids, polyols, in particular C 2 to C 10 polyols, such as glycerol, sorbitol, butylene glycol and polyethylene glycol, urea, allantoin, sugars and sugar derivatives, water-soluble vitamins, starch, or bacterial or plant extracts, such as those of aloe vera.
• retinol vitamin A
• tocopherol vitamin E
• ceramides essential oils and nonsaponifiable materials (tocotrienol, sesamin, ⁇ -oryzanol, phytosterols, squalenes, waxes or terpenes).
• a composition of the disclosure is devoid of vitamin A.
• the lysate in accordance with the disclosure can be employed in a topical composition with an agent which is active with regard to the epidermides, in particular dry epidermides.
• moistureturizing active principle is understood to mean:
• These compounds can represent from 0.001% to 30% and preferably from 0.01 to 20% of the total weight of the composition according to the disclosure.
• Mention may be made, by way of illustration, of vitamins, minerals, essential lipids, trace elements, polyphenols, flavonoids, phyto-oestrogens, antioxidants, such as lipoic acid and coenzyme Q10, carotenoids, prebiotics, proteins and amino acids, mono- and polysaccharides, amino sugars, phytosterols and triterpene alcohols of plant origin.
• vitamins A, C, D, E, PP and of the group B are in particular vitamins A, C, D, E, PP and of the group B.
• the choice has preferably been made, among carotenoids, of ⁇ -carotene, lycopene, lutein, zeazanthin and astaxanthin.
• the minerals and trace elements particularly employed are zinc, calcium, magnesium, copper, iron, iodine, manganese, selenium or chromium(III).
• the selection is also in particular made, among polyphenols, of grape, tea, olive, cocoa, coffee, potato, blueberry, elder, strawberry, cranberry and onion polyphenols.
• the selection is preferably made, among phyto-oestrogens, of isoflavones in the free or glycosylated form, such as genistein, daidzein or glycitein, or lignans, in particular those of flax and Schisandra chinensis.
• isoflavones in the free or glycosylated form, such as genistein, daidzein or glycitein, or lignans, in particular those of flax and Schisandra chinensis.
• Amino acids or the peptides and the proteins comprising them such as taurine, threonine, cysteine, tryptophan or methionine.
• the lipids preferably belong to the group of the oils comprising mono- and polyunsaturated fatty acids, such as oleic, linoleic, ⁇ -linolenic, ⁇ -linolenic or stearidonic acids, long-chain fish ⁇ -3 fatty acids, such as EPA and DHA, or conjugated fatty acids resulting from plant or animals, such as CLAs (Conjugated Linoleic Acid).
• mono- and polyunsaturated fatty acids such as oleic, linoleic, ⁇ -linolenic, ⁇ -linolenic or stearidonic acids, long-chain fish ⁇ -3 fatty acids, such as EPA and DHA, or conjugated fatty acids resulting from plant or animals, such as CLAs (Conjugated Linoleic Acid).
• the cosmetic treatment method of the disclosure can be employed in particular by administering the cosmetic and/or dermatological compositions or the combinations as defined above according to the usual technique for the use of these compositions.
• the cosmetic method according to the disclosure can thus be employed by topical administration, for example daily, of the lysate under consideration according to the disclosure.
• the method according to the disclosure can comprise a single administration.
• the administration is repeated, for example 2 to 3 times daily over a day or more and generally over a prolonged period of time of at least 4 weeks, indeed even 4 to 15 weeks, with, if appropriate, one or more periods of interruption.
• the percentages are percentages by weight and the ranges of values worded in the form “between . . . and . . . ” include the lower and upper limits specified.
• the ingredients are mixed, before they are formed, in the order and under conditions easily determined by a person skilled in the art.
• Cream for the care of the scalp % by weight Arachidyl behenyl alcohol/arachidyl glucoside 3.0 Isohexadecane 7.0 Bifidobacterium longum (lysate CLR) 5.00** (Repair Complex CLR ®)* Glycerol 2.0 Vitreoscilla filiformis extract 3.0 BHT 0.05 Methyl POB 0.1 Propyl POB 0.05 Water q.s. for 100 *Repair Complex CLR ® sold by K. Richter GmbH and corresponding to a formulation comprising 5% by weight of active principles **amount expressed as total product
• Cream for the care of the face % by weight Arachidyl behenyl alcohol/arachidyl glucoside 3.0 Isohexadecane 7.0 Bifidobacterium longum lysate (Repair Complex CLR ®)* 5.00** Glycerol 2.0 Vitreoscilla filiformis extract 3.0 BHT 0.05 Methyl POB 0.1 Propyl POB 0.05 Water q.s. for 100 *Repair Complex CLR ® sold by K. Richter GmbH and corresponding to a formulation comprising 5% by weight of active principles **amount expressed as total product
• the product tested is a Bifidobacterium longum lysate in disintegrated (with ultrasound) suspension in a weakly acidic aqueous medium, sold under the name Repair Complex CLR®.
• the active principle was tested alone in a randomized double blind study.
• This carrier formulation is an Arlacel/myrj® oil/demineralized water emulsion comprising 5% Parleam, 15% cyclopentasiloxane, 3% glycerol and 2% petrolatum.
• the subjects were evaluated at D1, D29, D43 and D57. On each visit, evaluations of the dryness of the legs were carried out by the dermatologist and by self-evaluation by the subjects according to the forms specified below.
• a sample is withdrawn from the external face of the leg at times D1, D29, D43 and D57 by varnish stripping in order to withdraw only a portion of the stratum corneum, i.e. at most 4 to 5 layers of stratum corneum.
• a 41 ⁇ m filter, type NY41 Millipore, nylon cloth (5 ⁇ 5 cm) is applied to a predefined area of the left leg.
• a transparent varnish with reference 614254/T.D. comprising: nitrocellulose 6.86 g; isopropanol 2.94 g; hypoallergenic alkyl resin 7.35 g; tributyl acetylcitrate 7.7 g; ethyl acetate 75.15 g; is then spread using a brush (15 mm) and then left to dry for 15 min. The nylon cloth is subsequently recovered using tweezers, the varnish strip being torn off with a sharp movement.
• the varnish strips are stored flat at ⁇ 20° C. in plastic bags.
• the results of the analysis by proteomics showed that the Bifidobacterium longum lysate stimulates the expression of various proteins which defend the epidermis from microorganisms such as the RNase 7, the dermcidin, the prolactin inducible protein (PiP), the proteins S100 A8 and A9, the histone protein of certain proteases involved in the phenomenon of desquamation (KLK7, KLK5, Cathepsin L2), while other proteins reflecting the metabolic immatunity of the cutaneous barrier see the decrease of their expression (Bleomycin hydrolase, Enolase 1, TP1, GAPDH).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Epidemiology (AREA)
• Birds (AREA)
• Biotechnology (AREA)
• Dermatology (AREA)
• Medicinal Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Tropical Medicine & Parasitology (AREA)
• Botany (AREA)
• Molecular Biology (AREA)
• Toxicology (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Cosmetics (AREA)

Priority Applications (3)

Applications Claiming Priority (4)

Related Child Applications (2)

Publications (1)

Family

ID=39271155

Family Applications (3)

Family Applications After (2)

Country Status (6)

Cited By (24)

Families Citing this family (20)

Citations (46)

Family Cites Families (60)

• 2007
  • 2007-09-04 FR FR0757348A patent/FR2920304B1/fr not_active Expired - Fee Related
• 2008
  • 2008-08-28 US US12/200,426 patent/US20090060962A1/en not_active Abandoned
  • 2008-09-03 JP JP2008225793A patent/JP5601765B2/ja active Active
  • 2008-09-03 ES ES08163551T patent/ES2705607T3/es active Active
  • 2008-09-03 EP EP08163551.8A patent/EP2033628B1/fr active Active
  • 2008-09-04 CN CN200810210591XA patent/CN101380289B/zh active Active
• 2012
  • 2012-05-15 US US13/471,730 patent/US20120231099A1/en not_active Abandoned
• 2018
  • 2018-05-01 US US15/967,657 patent/US11154731B2/en active Active

Patent Citations (53)

Also Published As

Similar Documents

Legal Events